Global Brain Disease Market

Brain Disease Comprehensive Study by Disease Type (Neurodegenerative Diseases, Neurovascular Diseases, Mental Disorders, Traumatic Brain Injuries), Distribution Channel (Hospitals Pharmacy, Online Pharmacy, Offline Pharmacy), Stages (Stage 1, Stage 2, Stage 3, Stage 4), Diagnosis Type (CT Scan, MRI, PET-CT Scan, Molecular Testing, EEG, Others), Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy) Players and Region - Global Market Outlook to 2028

Brain Disease Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Brain Disease
Brain disease is a type of central nervous system diseases. It refers to disabilities that affect the brain. There are various disability condition present in the brain disease such as brain deterioration, neurodegenerative diseases such as Alzheimer’s, Huntington’s disease and others. There are various symptoms of brain diseases such as headache, memory loss, tremors, increased reflexes, slurred speech, paralysis, and inability to concentrate among others. Surgery, radiation therapy, targeted therapy, chemotherapy and immunotherapy are the various treatment types used for brain disease. The brain disease market is a complex and challenging one, but it also holds immense potential for improving the lives of millions of people suffering from these debilitating conditions. By investing in research, development, and innovative technologies, we can work towards a future where brain diseases are not only treatable but even preventable.

AttributesDetails
Study Period2019-2028
Base Year2022
UnitValue (USD Million)


The brain disease market is expected to see continued growth and diversification in the coming years. As research progresses and technology advances, we can expect to see novel treatment options, personalized medicine approaches, and a greater role of digital health solutions. The competition will remain fierce, with players across different segments vying for market share and striving to make a meaningful impact on the lives of people suffering from brain diseases. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Brain Disease market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Eli Lilly (United States), F. Hoffmann La Roche AG (Switzerland), GE Healthcare (United States), Abbvie Inc. (United States), AC Immune SA (Switzerland), Allergan PLC (Ireland), Merck & Co (United States), Novartis AG (Switzerland) and AstraZeneca plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medtronic, Inc. (Ireland), Boston Scientific Corporation (United States), Delmar Pharmaceuticals Inc. (United States) and Omeros Corporation (United States).

Segmentation Overview
AMA Research has segmented the market of Global Brain Disease market by and Region.



On the basis of geography, the market of Brain Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Neurodegenerative Diseases will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospitals Pharmacy will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Stages, the sub-segment i.e. Stage 1 will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Type, the sub-segment i.e. CT Scan will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Surgery will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Government Support for Improving Healthcare System and Technological Advancement Related to Brain cancer

Market Growth Drivers:
Increasing Awareness of Brain Diseases and Their Treatments and Reducing Prices of Some Brain Disease Treatment

Challenges:
Lack of effective treatments

Restraints:
Contrary Effects with the Medications and Unfavorable Compensation Policies

Opportunities:
Increasing Health Care Expenditure in Developing Country and Escalating Therapeutic Applications of Brain Monitoring Devices

Market Leaders and their expansionary development strategies
In September 2023, The Michael J. Fox Foundation for Parkinson's Research partners with Amazon Web Services to create a massive database of Parkinson's disease data for research purposes.
In November 2023, The World Health Organization releases a report calling for increased investment in research and development for brain diseases, highlighting the significant global burden they pose.


Key Target Audience
Healthcare Research laboratories, Pharmaceuticals Industries, Medical Institutes, Medical Devices Manufactures, Medical Devices Distributors, Government Regulatory Bodies, Government Research Organizations, Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Disease Type
  • Neurodegenerative Diseases
  • Neurovascular Diseases
  • Mental Disorders
  • Traumatic Brain Injuries

By Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy
  • Offline Pharmacy

By Stages
  • Stage 1
  • Stage 2
  • Stage 3
  • Stage 4

By Diagnosis Type
  • CT Scan
  • MRI
  • PET-CT Scan
  • Molecular Testing
  • EEG
  • Others

By Treatment Type
  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness of Brain Diseases and Their Treatments
      • 3.2.2. Reducing Prices of Some Brain Disease Treatment
    • 3.3. Market Challenges
      • 3.3.1. Lack of effective treatments
    • 3.4. Market Trends
      • 3.4.1. Rising Government Support for Improving Healthcare System
      • 3.4.2. Technological Advancement Related to Brain cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Disease, by Disease Type, Distribution Channel, Stages, Diagnosis Type, Treatment Type and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Brain Disease (Value)
      • 5.2.1. Global Brain Disease by: Disease Type (Value)
        • 5.2.1.1. Neurodegenerative Diseases
        • 5.2.1.2. Neurovascular Diseases
        • 5.2.1.3. Mental Disorders
        • 5.2.1.4. Traumatic Brain Injuries
      • 5.2.2. Global Brain Disease by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals Pharmacy
        • 5.2.2.2. Online Pharmacy
        • 5.2.2.3. Offline Pharmacy
      • 5.2.3. Global Brain Disease by: Stages (Value)
        • 5.2.3.1. Stage 1
        • 5.2.3.2. Stage 2
        • 5.2.3.3. Stage 3
        • 5.2.3.4. Stage 4
      • 5.2.4. Global Brain Disease by: Diagnosis Type (Value)
        • 5.2.4.1. CT Scan
        • 5.2.4.2. MRI
        • 5.2.4.3. PET-CT Scan
        • 5.2.4.4. Molecular Testing
        • 5.2.4.5. EEG
        • 5.2.4.6. Others
      • 5.2.5. Global Brain Disease by: Treatment Type (Value)
        • 5.2.5.1. Surgery
        • 5.2.5.2. Radiation Therapy
        • 5.2.5.3. Targeted Therapy
        • 5.2.5.4. Chemotherapy
        • 5.2.5.5. Immunotherapy
      • 5.2.6. Global Brain Disease Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Brain Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann La Roche AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbvie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AC Immune SA (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan PLC (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Brain Disease Sale, by Disease Type, Distribution Channel, Stages, Diagnosis Type, Treatment Type and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Brain Disease (Value)
      • 7.2.1. Global Brain Disease by: Disease Type (Value)
        • 7.2.1.1. Neurodegenerative Diseases
        • 7.2.1.2. Neurovascular Diseases
        • 7.2.1.3. Mental Disorders
        • 7.2.1.4. Traumatic Brain Injuries
      • 7.2.2. Global Brain Disease by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals Pharmacy
        • 7.2.2.2. Online Pharmacy
        • 7.2.2.3. Offline Pharmacy
      • 7.2.3. Global Brain Disease by: Stages (Value)
        • 7.2.3.1. Stage 1
        • 7.2.3.2. Stage 2
        • 7.2.3.3. Stage 3
        • 7.2.3.4. Stage 4
      • 7.2.4. Global Brain Disease by: Diagnosis Type (Value)
        • 7.2.4.1. CT Scan
        • 7.2.4.2. MRI
        • 7.2.4.3. PET-CT Scan
        • 7.2.4.4. Molecular Testing
        • 7.2.4.5. EEG
        • 7.2.4.6. Others
      • 7.2.5. Global Brain Disease by: Treatment Type (Value)
        • 7.2.5.1. Surgery
        • 7.2.5.2. Radiation Therapy
        • 7.2.5.3. Targeted Therapy
        • 7.2.5.4. Chemotherapy
        • 7.2.5.5. Immunotherapy
      • 7.2.6. Global Brain Disease Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Disease: by Disease Type(USD Million)
  • Table 2. Brain Disease Neurodegenerative Diseases , by Region USD Million (2017-2022)
  • Table 3. Brain Disease Neurovascular Diseases , by Region USD Million (2017-2022)
  • Table 4. Brain Disease Mental Disorders , by Region USD Million (2017-2022)
  • Table 5. Brain Disease Traumatic Brain Injuries , by Region USD Million (2017-2022)
  • Table 6. Brain Disease: by Distribution Channel(USD Million)
  • Table 7. Brain Disease Hospitals Pharmacy , by Region USD Million (2017-2022)
  • Table 8. Brain Disease Online Pharmacy , by Region USD Million (2017-2022)
  • Table 9. Brain Disease Offline Pharmacy , by Region USD Million (2017-2022)
  • Table 10. Brain Disease: by Stages(USD Million)
  • Table 11. Brain Disease Stage 1 , by Region USD Million (2017-2022)
  • Table 12. Brain Disease Stage 2 , by Region USD Million (2017-2022)
  • Table 13. Brain Disease Stage 3 , by Region USD Million (2017-2022)
  • Table 14. Brain Disease Stage 4 , by Region USD Million (2017-2022)
  • Table 15. Brain Disease: by Diagnosis Type(USD Million)
  • Table 16. Brain Disease CT Scan , by Region USD Million (2017-2022)
  • Table 17. Brain Disease MRI , by Region USD Million (2017-2022)
  • Table 18. Brain Disease PET-CT Scan , by Region USD Million (2017-2022)
  • Table 19. Brain Disease Molecular Testing , by Region USD Million (2017-2022)
  • Table 20. Brain Disease EEG , by Region USD Million (2017-2022)
  • Table 21. Brain Disease Others , by Region USD Million (2017-2022)
  • Table 22. Brain Disease: by Treatment Type(USD Million)
  • Table 23. Brain Disease Surgery , by Region USD Million (2017-2022)
  • Table 24. Brain Disease Radiation Therapy , by Region USD Million (2017-2022)
  • Table 25. Brain Disease Targeted Therapy , by Region USD Million (2017-2022)
  • Table 26. Brain Disease Chemotherapy , by Region USD Million (2017-2022)
  • Table 27. Brain Disease Immunotherapy , by Region USD Million (2017-2022)
  • Table 28. South America Brain Disease, by Country USD Million (2017-2022)
  • Table 29. South America Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 30. South America Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 31. South America Brain Disease, by Stages USD Million (2017-2022)
  • Table 32. South America Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 33. South America Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 34. Brazil Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 35. Brazil Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 36. Brazil Brain Disease, by Stages USD Million (2017-2022)
  • Table 37. Brazil Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 38. Brazil Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 39. Argentina Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 40. Argentina Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 41. Argentina Brain Disease, by Stages USD Million (2017-2022)
  • Table 42. Argentina Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 43. Argentina Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 44. Rest of South America Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 45. Rest of South America Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 46. Rest of South America Brain Disease, by Stages USD Million (2017-2022)
  • Table 47. Rest of South America Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 48. Rest of South America Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 49. Asia Pacific Brain Disease, by Country USD Million (2017-2022)
  • Table 50. Asia Pacific Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 51. Asia Pacific Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 52. Asia Pacific Brain Disease, by Stages USD Million (2017-2022)
  • Table 53. Asia Pacific Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 54. Asia Pacific Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 55. China Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 56. China Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 57. China Brain Disease, by Stages USD Million (2017-2022)
  • Table 58. China Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 59. China Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 60. Japan Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 61. Japan Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 62. Japan Brain Disease, by Stages USD Million (2017-2022)
  • Table 63. Japan Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 64. Japan Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 65. India Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 66. India Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 67. India Brain Disease, by Stages USD Million (2017-2022)
  • Table 68. India Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 69. India Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 70. South Korea Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 71. South Korea Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 72. South Korea Brain Disease, by Stages USD Million (2017-2022)
  • Table 73. South Korea Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 74. South Korea Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 75. Taiwan Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 76. Taiwan Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 77. Taiwan Brain Disease, by Stages USD Million (2017-2022)
  • Table 78. Taiwan Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 79. Taiwan Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 80. Australia Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 81. Australia Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 82. Australia Brain Disease, by Stages USD Million (2017-2022)
  • Table 83. Australia Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 84. Australia Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Brain Disease, by Stages USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 90. Europe Brain Disease, by Country USD Million (2017-2022)
  • Table 91. Europe Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 92. Europe Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 93. Europe Brain Disease, by Stages USD Million (2017-2022)
  • Table 94. Europe Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 95. Europe Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 96. Germany Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 97. Germany Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 98. Germany Brain Disease, by Stages USD Million (2017-2022)
  • Table 99. Germany Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 100. Germany Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 101. France Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 102. France Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 103. France Brain Disease, by Stages USD Million (2017-2022)
  • Table 104. France Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 105. France Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 106. Italy Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 107. Italy Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 108. Italy Brain Disease, by Stages USD Million (2017-2022)
  • Table 109. Italy Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 110. Italy Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 111. United Kingdom Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 112. United Kingdom Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 113. United Kingdom Brain Disease, by Stages USD Million (2017-2022)
  • Table 114. United Kingdom Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 115. United Kingdom Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 116. Netherlands Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 117. Netherlands Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 118. Netherlands Brain Disease, by Stages USD Million (2017-2022)
  • Table 119. Netherlands Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 120. Netherlands Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 121. Rest of Europe Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 122. Rest of Europe Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 123. Rest of Europe Brain Disease, by Stages USD Million (2017-2022)
  • Table 124. Rest of Europe Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 125. Rest of Europe Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 126. MEA Brain Disease, by Country USD Million (2017-2022)
  • Table 127. MEA Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 128. MEA Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 129. MEA Brain Disease, by Stages USD Million (2017-2022)
  • Table 130. MEA Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 131. MEA Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 132. Middle East Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 133. Middle East Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 134. Middle East Brain Disease, by Stages USD Million (2017-2022)
  • Table 135. Middle East Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 136. Middle East Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 137. Africa Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 138. Africa Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 139. Africa Brain Disease, by Stages USD Million (2017-2022)
  • Table 140. Africa Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 141. Africa Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 142. North America Brain Disease, by Country USD Million (2017-2022)
  • Table 143. North America Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 144. North America Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 145. North America Brain Disease, by Stages USD Million (2017-2022)
  • Table 146. North America Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 147. North America Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 148. United States Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 149. United States Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 150. United States Brain Disease, by Stages USD Million (2017-2022)
  • Table 151. United States Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 152. United States Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 153. Canada Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 154. Canada Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 155. Canada Brain Disease, by Stages USD Million (2017-2022)
  • Table 156. Canada Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 157. Canada Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 158. Mexico Brain Disease, by Disease Type USD Million (2017-2022)
  • Table 159. Mexico Brain Disease, by Distribution Channel USD Million (2017-2022)
  • Table 160. Mexico Brain Disease, by Stages USD Million (2017-2022)
  • Table 161. Mexico Brain Disease, by Diagnosis Type USD Million (2017-2022)
  • Table 162. Mexico Brain Disease, by Treatment Type USD Million (2017-2022)
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Brain Disease: by Disease Type(USD Million)
  • Table 174. Brain Disease Neurodegenerative Diseases , by Region USD Million (2023-2028)
  • Table 175. Brain Disease Neurovascular Diseases , by Region USD Million (2023-2028)
  • Table 176. Brain Disease Mental Disorders , by Region USD Million (2023-2028)
  • Table 177. Brain Disease Traumatic Brain Injuries , by Region USD Million (2023-2028)
  • Table 178. Brain Disease: by Distribution Channel(USD Million)
  • Table 179. Brain Disease Hospitals Pharmacy , by Region USD Million (2023-2028)
  • Table 180. Brain Disease Online Pharmacy , by Region USD Million (2023-2028)
  • Table 181. Brain Disease Offline Pharmacy , by Region USD Million (2023-2028)
  • Table 182. Brain Disease: by Stages(USD Million)
  • Table 183. Brain Disease Stage 1 , by Region USD Million (2023-2028)
  • Table 184. Brain Disease Stage 2 , by Region USD Million (2023-2028)
  • Table 185. Brain Disease Stage 3 , by Region USD Million (2023-2028)
  • Table 186. Brain Disease Stage 4 , by Region USD Million (2023-2028)
  • Table 187. Brain Disease: by Diagnosis Type(USD Million)
  • Table 188. Brain Disease CT Scan , by Region USD Million (2023-2028)
  • Table 189. Brain Disease MRI , by Region USD Million (2023-2028)
  • Table 190. Brain Disease PET-CT Scan , by Region USD Million (2023-2028)
  • Table 191. Brain Disease Molecular Testing , by Region USD Million (2023-2028)
  • Table 192. Brain Disease EEG , by Region USD Million (2023-2028)
  • Table 193. Brain Disease Others , by Region USD Million (2023-2028)
  • Table 194. Brain Disease: by Treatment Type(USD Million)
  • Table 195. Brain Disease Surgery , by Region USD Million (2023-2028)
  • Table 196. Brain Disease Radiation Therapy , by Region USD Million (2023-2028)
  • Table 197. Brain Disease Targeted Therapy , by Region USD Million (2023-2028)
  • Table 198. Brain Disease Chemotherapy , by Region USD Million (2023-2028)
  • Table 199. Brain Disease Immunotherapy , by Region USD Million (2023-2028)
  • Table 200. South America Brain Disease, by Country USD Million (2023-2028)
  • Table 201. South America Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 202. South America Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 203. South America Brain Disease, by Stages USD Million (2023-2028)
  • Table 204. South America Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 205. South America Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 206. Brazil Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 207. Brazil Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 208. Brazil Brain Disease, by Stages USD Million (2023-2028)
  • Table 209. Brazil Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 210. Brazil Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 211. Argentina Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 212. Argentina Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 213. Argentina Brain Disease, by Stages USD Million (2023-2028)
  • Table 214. Argentina Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 215. Argentina Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 216. Rest of South America Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 217. Rest of South America Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 218. Rest of South America Brain Disease, by Stages USD Million (2023-2028)
  • Table 219. Rest of South America Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 220. Rest of South America Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 221. Asia Pacific Brain Disease, by Country USD Million (2023-2028)
  • Table 222. Asia Pacific Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 223. Asia Pacific Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 224. Asia Pacific Brain Disease, by Stages USD Million (2023-2028)
  • Table 225. Asia Pacific Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 226. Asia Pacific Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 227. China Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 228. China Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 229. China Brain Disease, by Stages USD Million (2023-2028)
  • Table 230. China Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 231. China Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 232. Japan Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 233. Japan Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 234. Japan Brain Disease, by Stages USD Million (2023-2028)
  • Table 235. Japan Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 236. Japan Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 237. India Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 238. India Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 239. India Brain Disease, by Stages USD Million (2023-2028)
  • Table 240. India Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 241. India Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 242. South Korea Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 243. South Korea Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 244. South Korea Brain Disease, by Stages USD Million (2023-2028)
  • Table 245. South Korea Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 246. South Korea Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 247. Taiwan Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 248. Taiwan Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 249. Taiwan Brain Disease, by Stages USD Million (2023-2028)
  • Table 250. Taiwan Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 251. Taiwan Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 252. Australia Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 253. Australia Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 254. Australia Brain Disease, by Stages USD Million (2023-2028)
  • Table 255. Australia Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 256. Australia Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Brain Disease, by Stages USD Million (2023-2028)
  • Table 260. Rest of Asia-Pacific Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 261. Rest of Asia-Pacific Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 262. Europe Brain Disease, by Country USD Million (2023-2028)
  • Table 263. Europe Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 264. Europe Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 265. Europe Brain Disease, by Stages USD Million (2023-2028)
  • Table 266. Europe Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 267. Europe Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 268. Germany Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 269. Germany Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 270. Germany Brain Disease, by Stages USD Million (2023-2028)
  • Table 271. Germany Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 272. Germany Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 273. France Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 274. France Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 275. France Brain Disease, by Stages USD Million (2023-2028)
  • Table 276. France Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 277. France Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 278. Italy Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 279. Italy Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 280. Italy Brain Disease, by Stages USD Million (2023-2028)
  • Table 281. Italy Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 282. Italy Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 283. United Kingdom Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 284. United Kingdom Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 285. United Kingdom Brain Disease, by Stages USD Million (2023-2028)
  • Table 286. United Kingdom Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 287. United Kingdom Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 288. Netherlands Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 289. Netherlands Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 290. Netherlands Brain Disease, by Stages USD Million (2023-2028)
  • Table 291. Netherlands Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 292. Netherlands Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 293. Rest of Europe Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 294. Rest of Europe Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 295. Rest of Europe Brain Disease, by Stages USD Million (2023-2028)
  • Table 296. Rest of Europe Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 297. Rest of Europe Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 298. MEA Brain Disease, by Country USD Million (2023-2028)
  • Table 299. MEA Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 300. MEA Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 301. MEA Brain Disease, by Stages USD Million (2023-2028)
  • Table 302. MEA Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 303. MEA Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 304. Middle East Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 305. Middle East Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 306. Middle East Brain Disease, by Stages USD Million (2023-2028)
  • Table 307. Middle East Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 308. Middle East Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 309. Africa Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 310. Africa Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 311. Africa Brain Disease, by Stages USD Million (2023-2028)
  • Table 312. Africa Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 313. Africa Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 314. North America Brain Disease, by Country USD Million (2023-2028)
  • Table 315. North America Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 316. North America Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 317. North America Brain Disease, by Stages USD Million (2023-2028)
  • Table 318. North America Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 319. North America Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 320. United States Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 321. United States Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 322. United States Brain Disease, by Stages USD Million (2023-2028)
  • Table 323. United States Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 324. United States Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 325. Canada Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 326. Canada Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 327. Canada Brain Disease, by Stages USD Million (2023-2028)
  • Table 328. Canada Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 329. Canada Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 330. Mexico Brain Disease, by Disease Type USD Million (2023-2028)
  • Table 331. Mexico Brain Disease, by Distribution Channel USD Million (2023-2028)
  • Table 332. Mexico Brain Disease, by Stages USD Million (2023-2028)
  • Table 333. Mexico Brain Disease, by Diagnosis Type USD Million (2023-2028)
  • Table 334. Mexico Brain Disease, by Treatment Type USD Million (2023-2028)
  • Table 335. Research Programs/Design for This Report
  • Table 336. Key Data Information from Secondary Sources
  • Table 337. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Disease: by Disease Type USD Million (2017-2022)
  • Figure 5. Global Brain Disease: by Distribution Channel USD Million (2017-2022)
  • Figure 6. Global Brain Disease: by Stages USD Million (2017-2022)
  • Figure 7. Global Brain Disease: by Diagnosis Type USD Million (2017-2022)
  • Figure 8. Global Brain Disease: by Treatment Type USD Million (2017-2022)
  • Figure 9. South America Brain Disease Share (%), by Country
  • Figure 10. Asia Pacific Brain Disease Share (%), by Country
  • Figure 11. Europe Brain Disease Share (%), by Country
  • Figure 12. MEA Brain Disease Share (%), by Country
  • Figure 13. North America Brain Disease Share (%), by Country
  • Figure 14. Global Brain Disease share by Players 2022 (%)
  • Figure 15. Global Brain Disease share by Players (Top 3) 2022(%)
  • Figure 16. Global Brain Disease share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 20. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly (United States) Revenue: by Geography 2022
  • Figure 22. F. Hoffmann La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann La Roche AG (Switzerland) Revenue: by Geography 2022
  • Figure 24. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 25. GE Healthcare (United States) Revenue: by Geography 2022
  • Figure 26. Abbvie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbvie Inc. (United States) Revenue: by Geography 2022
  • Figure 28. AC Immune SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. AC Immune SA (Switzerland) Revenue: by Geography 2022
  • Figure 30. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 31. Allergan PLC (Ireland) Revenue: by Geography 2022
  • Figure 32. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck & Co (United States) Revenue: by Geography 2022
  • Figure 34. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 36. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 38. Global Brain Disease: by Disease Type USD Million (2023-2028)
  • Figure 39. Global Brain Disease: by Distribution Channel USD Million (2023-2028)
  • Figure 40. Global Brain Disease: by Stages USD Million (2023-2028)
  • Figure 41. Global Brain Disease: by Diagnosis Type USD Million (2023-2028)
  • Figure 42. Global Brain Disease: by Treatment Type USD Million (2023-2028)
  • Figure 43. South America Brain Disease Share (%), by Country
  • Figure 44. Asia Pacific Brain Disease Share (%), by Country
  • Figure 45. Europe Brain Disease Share (%), by Country
  • Figure 46. MEA Brain Disease Share (%), by Country
  • Figure 47. North America Brain Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Eli Lilly (United States)
  • F. Hoffmann La Roche AG (Switzerland)
  • GE Healthcare (United States)
  • Abbvie Inc. (United States)
  • AC Immune SA (Switzerland)
  • Allergan PLC (Ireland)
  • Merck & Co (United States)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (United Kingdom)
Additional players considered in the study are as follows:
Medtronic, Inc. (Ireland) , Boston Scientific Corporation (United States) , Delmar Pharmaceuticals Inc. (United States) , Omeros Corporation (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 210 Pages 61 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brain Disease Market Quantitative research analysis
Global Brain Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Eli Lilly (United States), F. Hoffmann La Roche AG (Switzerland), GE Healthcare (United States), Abbvie Inc. (United States), AC Immune SA (Switzerland), Allergan PLC (Ireland), Merck & Co (United States), Novartis AG (Switzerland) and AstraZeneca plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Government Support for Improving Healthcare System " is seen as one of major influencing trends for Brain Disease Market during projected period 2022-2028.
The Brain Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Brain Disease Market Report?

Have a Query? Click Here

Other Related Reports

Plasma Fractionation Comprehensive Study by Type (Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others), Application (Immunology, Hematology, Neurology, Others), End...
$ 3750
Endometriosis Therapies Comprehensive Study by Type (Hormonal Therapy (Oral Contraceptive Pills, Progestins), Hormone Replacement Therapy (GnRH Agonists, Luteinizing-hormone-releasing hormone recepto...
$ 3750
Thyroid Gland Disorder Treatment Comprehensive Study by Type (Medication, Surgery), Application (Men, Women), Diagnosis (Blood Tests, Imaging Tests, Physical Exams), Disorder Type (Hypothyroidism, Hy...
$ 3450
Lumbar Spine Fusion Comprehensive Study by Type (Anterior lumbar interbody fusion, Lateral lumbar interbody fusion, Posterior lumbar interbody fusion, Others), Application (Hospitals, Ambulatory Surg...
$ 3750
Liver Cirrhosis Comprehensive Study by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis), Application (Hospitals, Specialty Clinics, Others),...
$ 3750
Simvastatin Comprehensive Study by Type (Enzymatic Synthesis, Chemical Synthesis), Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Form type (Tablet, Capsule) Players and Region - ...
$ 3500